A Study to Evaluate the Efficacy and Safety of Birtamimab in Mayo Stage IV Patients With AL Amyloidosis

NCT04973137 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

208

Enrollment

INDUSTRY

Sponsor class

Stopped The AFFIRM-AL clinical trial did not meet its primary endpoint.

Conditions

Light Chain (AL) Amyloidosis

Interventions

DRUG: Birtamimab
OTHER: Placebo
DRUG: Standard of Care Chemotherapy

Sponsor

Prothena Biosciences Ltd.